Zai Lab Ltd (ZLAB) FinancialsZLABFinancialZai Lab Ltd

Zai Lab Ltd (ZLAB) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is ZEJULA, accounting for 30.3% of total sales, equivalent to $32.08M. Other significant revenue streams include VYVGART and NUZYRA. Understanding this composition is critical for investors evaluating how ZLAB navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Zai Lab Ltd maintains a gross margin of 60.25%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -66.40%, while the net margin is -47.81%. These profitability ratios, combined with a Return on Equity (ROE) of -26.91%, provide a clear picture of how effectively ZLAB converts its operational activities into shareholder value.

In the context of the broader market, ZLAB competes directly with industry leaders such as UTHR and BNTX. With a market capitalization of $2.91B, it holds a significant position in the sector. When comparing efficiency, ZLAB's gross margin of 60.25% stands against UTHR's 87.30% and BNTX's 8.14%. Such benchmarking helps identify whether Zai Lab Ltd is trading at a premium or discount relative to its financial performance.

Zai Lab reported a Q2 revenue of $106.3 million, which beat expectations by $2.5 million, although it still reflects a 3.4% decline year-over-year. The gross margin stands at 60.25%, showcasing decent profitability despite ongoing losses.